<DOC>
	<DOCNO>NCT00038311</DOCNO>
	<brief_summary>Intensive chemotherapy associate significant thrombocytopenia , often require platelet transfusion maintain platelet count . This investigational drug demonstrate ability increase platelet count . This study test safety efficacy investigational drug prevention thrombocytopenia patient high-risk sarcoma receiving AI ( Adriamycin/Ifosfamide ) chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy ( PN-152,243 ) /PN-196,444 Prevention Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Patients must newly diagnose moderate highgrade sarcoma receive AI ( Adriamycin/Ifosfamide ) chemotherapy Patients must active bleeding ( exclusion apply ) history platelet disorder</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>